← feed

Is NCT03443960 results overdue?

Yes — results are overdue. Primary completion was 2018-04-09; the FDAAA-801 reporting deadline (2019-04-09) passed 2676 days ago and no results are posted on ClinicalTrials.gov.

Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules

NCT IDNCT03443960 ↗
SponsorTonix Pharmaceuticals, Inc. (INDUSTRY)
Public issuerTonix Pharmaceuticals Holding Corp. — TNXP (CIK 0001430306) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-04-09 (ACTUAL)
Reporting deadline2019-04-09 (completion + 365d)
Days overdue2676
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 1f45f42b0c24f90d… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03443960. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →